Treatment Study of Non-Metastatic Desmoplastic Medulloblastoma in Children
The ACNS 1221 study is a single arm multi institutional trial for newly diagnosed young children (0- <4 years of age at study enrollment) with nodular desmoplastic or medulloblastoma with extensive nodularity (MO ND/MBEN medulloblastoma). The primary objective is estimating the progression-free survival distribution associated with treatment as per HITSKK 2000 protocol without intraventricular methotrexate.
In order to participate you must meet the following criteria:
- Are less than 48 months old (4 years of age) at time of definitive surgery.
- Have been newly diagnosed and have a confirmed histologic diagnosis of nodular desmoplastic (NO) medulloblastoma or medulloblastoma with extensive nodularity (MBEN) from rapid central pathology screening review.
This is a partial list of elgibility requirements.